Literature DB >> 19570715

Current and potential inflammation targeted therapies in head and neck cancer.

Frederick Wang1, Pattatheyil Arun, Jay Friedman, Zhong Chen, Carter Van Waes.   

Abstract

Inflammation often exists in the tumor microenvironment and is induced by inflammatory mediators (cytokines, chemokines, and growth factors) produced by the tumor, stroma, and infiltrating cells. These factors modulate tissue remodeling and angiogenesis and actively promote tumor cell survival and chemoresistance through autocrine and paracrine mechanisms. Head and neck squamous cell carcinomas (HNSCCs) are highly inflammatory and aggressive in nature, and they express a number of cytokines and growth factors involved in inflammation. These cytokines and growth factors activate important signal transduction pathways, including NF-kappaB, JAK/STAT, and PI3K/Akt/mTOR, which regulate the expression of genes controlling growth, survival, and chemosensitivity. This review provides an update on recent advances in the understanding of the mechanisms driving cancer-related inflammation in HNSCC and on molecular targeted therapies under preclinical and clinical investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19570715      PMCID: PMC2731001          DOI: 10.1016/j.coph.2009.06.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  47 in total

1.  Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells.

Authors:  Ming Yu; Jason Yeh; Carter Van Waes
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

Review 2.  Role of cytokines in head and neck squamous cell carcinoma.

Authors:  Ralph Pries; Stefan Nitsch; Barbara Wollenberg
Journal:  Expert Rev Anticancer Ther       Date:  2006-09       Impact factor: 4.512

3.  Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.

Authors:  Tin Lap Lee; Jason Yeh; Carter Van Waes; Zhong Chen
Journal:  Mol Cancer Ther       Date:  2006-01       Impact factor: 6.261

Review 4.  STAT3 as a therapeutic target in head and neck cancer.

Authors:  Rebecca J Leeman; Vivian Wai Yan Lui; Jennifer Rubin Grandis
Journal:  Expert Opin Biol Ther       Date:  2006-03       Impact factor: 4.388

5.  The antioxidant function of the p53 tumor suppressor.

Authors:  Anna A Sablina; Andrei V Budanov; Galina V Ilyinskaya; Larissa S Agapova; Julia E Kravchenko; Peter M Chumakov
Journal:  Nat Med       Date:  2005-11-13       Impact factor: 53.440

6.  Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.

Authors:  Panomwat Amornphimoltham; Vyomesh Patel; Akrit Sodhi; Nikolaos G Nikitakis; John J Sauk; Edward A Sausville; Alfredo A Molinolo; J Silvio Gutkind
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

Review 7.  Nuclear factor-kappaB in development, prevention, and therapy of cancer.

Authors:  Carter Van Waes
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

8.  Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.

Authors:  Jianming Duan; Jay Friedman; Liesl Nottingham; Zhong Chen; Gulshan Ara; Carter Van Waes
Journal:  Mol Cancer Ther       Date:  2007-01       Impact factor: 6.261

9.  Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma.

Authors:  Brian Worden; Xin Ping Yang; Tin Lap Lee; Lorena Bagain; Ning T Yeh; Joshua G Cohen; Carter Van Waes; Zhong Chen
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

Review 10.  Interleukin 6: from bench to bedside.

Authors:  Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Nat Clin Pract Rheumatol       Date:  2006-11
View more
  42 in total

1.  Human β-defensin 3 promotes NF-κB-mediated CCR7 expression and anti-apoptotic signals in squamous cell carcinoma of the head and neck.

Authors:  Yvonne K Mburu; Koji Abe; Laura K Ferris; Saumendra N Sarkar; Robert L Ferris
Journal:  Carcinogenesis       Date:  2010-11-11       Impact factor: 4.944

2.  Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.

Authors:  Yuan Zhao; Yubin Hao; Hongguang Ji; Yayin Fang; Yinhan Guo; Wei Sha; Yanfei Zhou; Xiaowu Pang; William M Southerland; Joseph A Califano; Xinbin Gu
Journal:  Cancer Prev Res (Phila)       Date:  2010-05-25

3.  Nerve growth factor links oral cancer progression, pain, and cachexia.

Authors:  Yi Ye; Dongmin Dang; Jianan Zhang; Chi T Viet; David K Lam; John C Dolan; Jennifer L Gibbs; Brian L Schmidt
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

4.  The diacylglycerol kinase α (DGKα)/Akt/NF-κB feedforward loop promotes esophageal squamous cell carcinoma (ESCC) progression via FAK-dependent and FAK-independent manner.

Authors:  Jie Chen; Weimin Zhang; Yan Wang; Di Zhao; Mengjiao Wu; Jiawen Fan; Jinting Li; Ying Gong; Nana Dan; Di Yang; Rui Liu; Qimin Zhan
Journal:  Oncogene       Date:  2018-12-07       Impact factor: 9.867

5.  Neurocognitive function in head and neck cancer patients prior to treatment.

Authors:  Stewart M Bond; Mary S Dietrich; Barbara A Murphy
Journal:  Support Care Cancer       Date:  2011-01-13       Impact factor: 3.603

6.  A role of sphingosine kinase 1 in head and neck carcinogenesis.

Authors:  Keisuke Shirai; Tatsuya Kaneshiro; Masayuki Wada; Hideki Furuya; Jacek Bielawski; Yusuf A Hannun; Lina M Obeid; Besim Ogretmen; Toshihiko Kawamori
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-05

7.  Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.

Authors:  Jipei Liao; Zejia Yang; Brandon Carter-Cooper; Elizabeth T Chang; Eun Yong Choi; Bhaskar Kallakury; Xuefeng Liu; Rena G Lapidus; Kevin J Cullen; Hancai Dan
Journal:  Clin Exp Metastasis       Date:  2020-02-04       Impact factor: 5.150

8.  NFκB activation demarcates a subset of hepatocellular carcinoma patients for targeted therapy.

Authors:  Vignesh Ramesh; Karthikeyan Selvarasu; Jaishree Pandian; Soundarajan Myilsamy; Chidambaranathan Shanmugasundaram; Kumaresan Ganesan
Journal:  Cell Oncol (Dordr)       Date:  2016-08-25       Impact factor: 6.730

9.  Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models.

Authors:  R Minelli; S Occhipinti; C L Gigliotti; G Barrera; P Gasco; L Conti; A Chiocchetti; G P Zara; R Fantozzi; M Giovarelli; U Dianzani; C Dianzani
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 10.  Mononuclear phagocytes in head and neck squamous cell carcinoma.

Authors:  Kenneth Wilfried Kross; John-Helge Heimdal; Hans Jørgen Aarstad
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-12-05       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.